11 research outputs found

    Relationship of betel nut, tobacco, smoking, and alcohol and status of hr-HPV in Oral cavity patients only.

    No full text
    <p>* Statistically Significant OR = odds ratio; CI = confidence interval;</p><p><sup>ā€ </sup> Reference group for OR calculation</p><p>Relationship of betel nut, tobacco, smoking, and alcohol and status of hr-HPV in Oral cavity patients only.</p

    Demographic profiles and association with hr- HPV Positivity-.

    No full text
    <p>* Statistically Significant; OR = odds ratio; CI = confidence interval;</p><p><sup>ā€ </sup> Reference group for OR calculation. Since only one variable is significant that will be significant in multivariate analysis also</p><p>Demographic profiles and association with hr- HPV Positivity-.</p

    Relation of HPV -16 and HPV-18 with clinico-pathological characteristics.

    No full text
    <p>* Statistically Significant, OR = odds ratio; CI = confidence interval;</p><p><sup>ā€ </sup> Reference group for OR calculation</p><p>Relation of HPV -16 and HPV-18 with clinico-pathological characteristics.</p

    Relationship between clinico-pathological characteristics and hr- HPV Positivity.

    No full text
    <p>* Statistically Significant OR = odds ratio; CI = confidence interval;</p><p><sup>ā€ </sup> Reference group for OR calculation</p><p>Relationship between clinico-pathological characteristics and hr- HPV Positivity.</p

    Aptamer-Assisted Detection of the Altered Expression of Estrogen Receptor Alpha in Human Breast Cancer

    No full text
    <div><p>An increase in the expression of estrogen receptors (ER) and the expanded population of ER-positive cells are two common phenotypes of breast cancer. Detection of the aberrantly expressed ERĪ± in breast cancer is carried out using ERĪ±-antibodies and radiolabelled ligands to make decisions about cancer treatment and targeted therapy. Capitalizing on the beneficial advantages of aptamer over the conventional antibody or radiolabelled ligand, we have identified a DNA aptamer that selectively binds and facilitates the detection of ERĪ± in human breast cancer tissue sections. The aptamer is identified using the high throughput sequencing assisted SELEX screening. Biophysical characterization confirms the binding and formation of a thermodynamically stable complex between the identified DNA aptamer (ERaptD4) and ERĪ± (<i>K</i>a = 1.55Ā±0.298Ɨ10<sup>8</sup> M<sup>-1</sup>; Ī”<i>H</i> = 4.32Ɨ10<sup>4</sup>Ā±801.1 cal/mol; Ī”<i>S</i> = -108 cal/mol/deg). Interestingly, the specificity measurements suggest that the ERaptD4 internalizes into ERĪ±-positive breast cancer cells in a target-selective manner and localizes specifically in the nuclear region. To harness these characteristics of ERaptD4 for detection of ERĪ± expression in breast cancer samples, we performed the aptamer-assisted histochemical analysis of ERĪ± in tissue samples from breast cancer patients. The results were validated by performing the immunohistochemistry on same samples with an ERĪ±-antibody. We found that the two methods agree strongly in assay output (kappa value = 0.930, p-value <0.05 for strong ERĪ± positive and the ERĪ± negative samples; kappa value = 0.823, p-value <0.05 for the weak/moderate ER+ve samples, n = 20). Further, the aptamer stain the ERĪ±-positive cells in breast tissues without cross-reacting to ERĪ±-deficient fibroblasts, adipocytes, or the inflammatory cells. Our results demonstrate a significant consistency in the aptamer-assisted detection of ERĪ± in strong ERĪ± positive, moderate ERĪ± positive and ERĪ± negative breast cancer tissues. We anticipate that the ERaptD4 aptamer targeting ERĪ± may potentially be used for an efficient grading of ERĪ± expression in cancer tissues.</p></div

    Specificity analysis of ERaptD4 using flow cytometry, fluorescent microscopy and cytochemistry.

    No full text
    <p>(<b>a1-a2</b>) Treatment of MCF-7 cells with fluorescent-tagged ERaptD4 produced a shift of 84% relative to unstained MCF-7 cells. Figure in inset provides the fluorescent microscopy image of the FAM-ERaptD4 treated cells. (<b>b1-b2</b>) A shift of 20% is observed in MDA-MB-231 cell upon treatment with fluorescent-labelled ERaptD4. (<b>c1-c2</b>) The treatment of MCF-7 cells with a random sequence (FAM-labelled non-enriched aptamer library) produced no shift, indicating the lack of binding by the random sequence. FAM-labelling of the non-enriched aptamer library is carried out using PCR amplification with FAM-forward primer and biotin-reverse primer. Strand separation is performed on streptavidin magnetic beads. (<b>d-e</b>) Aptacytochemistry of ERĪ±-positive MCF-7 and ERĪ±-deficient MDA-MB-231 cells. Size-bar on images a-c is 100 pixels (imaging at 63X). Size-bar on images d-e is 200 pixels (imaging at 20X).</p

    Analysis of the affinity and specificity of selected probable ERĪ±-aptamers.

    No full text
    <p>(<b>a</b>) Relative binding of selected DNA sequences is analyzed through an aptamer-assisted ELISA. ERĪ±-antibody is used as a positive control to normalize the binding. Non-enriched aptamer library is taken as negative control. (<b>b</b>) Target selectivity of selected sequences is analyzed in a similar manner using cellular extracts of MCF-7 and MDA-MB-231 cells. (<b>c</b>) ITC isotherms of ERĪ± interactions with aptamer ERaptD4 is determined by titrating aptamer (10 Ī¼M; in the syringe) into ERĪ± (1Ī¼M, 1.4 ml in sample cell). The top panel represents the raw heats of binding obtained upon titration of aptamer to ERĪ± protein. The lower panel is the binding isotherm fitted to the raw data using one site model.</p

    Staining of ERĪ±-positive cells in breast cancer tissue samples.

    No full text
    <p>A comparative analysis of the aptahistochemistry and immunohistochemistry methods is made by analyzing the expression of ERĪ± in breast tissue sections with ERĪ±-antibody (sc-543) and ERaptD4 aptamer. The 10 X and 40 X represents the two magnifications of same images stained using antibody or aptamer.</p

    Monitoring the aptamer enrichment.

    No full text
    <p>(<b>a</b>) Schematic representation of ERĪ± aptamer screening using modified SELEX method. (<b>b</b>) Monitoring the enrichment of ERĪ± binding sequences through photocolorimetric approach. The relative binding of enriched sequences (equivalent amounts) obtained after 2, 4, 6, 8 and 9<sup>th</sup> round of SELEX screening is analyzed through photocolorimetric method. The initial non-enriched library is used as a control sequence. (<b>c</b>) Copy number analysis (cut-off = 5) in the enriched DNA sequences obtained through Illumina sequencing.</p
    corecore